Table 1. Main characteristics of the included studies in our-analysis.
| Study | Journal | Date | Country | Sample size | Male:N(%) | Age:mean±SD | ||||
| Total | Survivor | Non-survivor | Survivor | Non-survivor | Survivor | Non-survivor | ||||
| Cao,J.L. | Clin Infect Dis | 2020/4/3 | China | 102 | 85 | 17 | 40(47%) | 13(76%) | 55.3±14.3 | 72±13.6 |
| Du, R. H. | Eur Respir J | 2020/4/10 | China | 179 | 158 | 21 | 87 (55%) | 10 (48%) | 56.0±13.5 | 70.2±7.7 |
| Wang, L. | J Infect | 2020/4/3 | China | 339 | 274 | 65 | 127(46%) | 39(60%) | 68.7±7.5 | 76.3±9.9 |
| Javanian, M. | Rom J Intern Med | 2020/5/13 | Iran | 100 | 81 | 19 | 39 (49%) | 12 (57%) | 57.7±13.6 | 69.3±11.1 |
| Li, Q.B. | Leukemia | 2020/6/13 | China | 1449 | 1327 | 122 | 643(48%) | 90(74%) | 53.7±17.8 | 70±11.3 |
| Okoh, A. K. | Int J Equity Health | 2020/6/12 | USA | 251 | 154 | 97 | 69 (45%) | 60 (62%) | 57.7±17.2 | 67±15.8 |
| Rath, D. | Clin Res Cardiol | 2020/6/17 | Germany | 123 | 107 | 16 | 65 (61%) | 12 (75%) | 67 ± 15 | 73 ± 16 |
| Khalil, K. | J Infect | 2020/6/21 | United Kingdom | 217 | 158 | 59 | 87 (55%) | 42 (71%) | 64.0±2.6 | 76.1±3.3 |
| Nowak, B. | Pol Arch Intern Med | 2020/5/19 | Poland | 169 | 123 | 46 | 57 (46%) | 30 (65%) | 59.3± 20.1 | 75.3 ±11.9 |
| Shahriarirad, R. | BMC Infect Dis | 2020/6/20 | Iran | 113 | 104 | 9 | 66 (93%) | 5 (7%) | / | / |
| Wang, K. | Clin Infect Dis | 2020/5/4 | China | 296 | 277 | 19 | 129 (47%) | 11 (58%) | 46.0 ± 14.4 | 65.6 ± 12.6 |
| Aloisio, E. | Arch Pathol Lab Med | 2020/7/11 | Italy | 427 | 338 | 89 | 223(66.0%) | 70(78.7%) | 58.3±15.6 | 73.3±9.8 |
| Baqui, P. | Lancet Glob Health | 2020/7/6 | Brazil | 7371 | 4043 | 3328 | 2300(56.9%) | 1990(59.8%) | 51.6±17.0 | 65.6±15.9 |
| Berenguer, J. | Clin Microbiol Infect | 2020/8/8 | Spain | 4035 | 2904 | 1131 | 1666(57.4%) | 767(67.8%) | 63.7±17.8 | 78.7±11.1 |
| Bonetti, G. | Clin Chem Lab Med | 2020/6/24 | Italy | 144 | 74 | 70 | 51(68.9%) | 45(64.3%) | 62.6±15.0 | 75.4±15.0 |
| Gayam, V. | J Med Virol | 2020/7/17 | USA | 408 | 276 | 132 | 155(56.2%) | 76(57.6%) | 63±14.9 | 71±13.5 |
| Liu, J. | Ann Intensive Care | 2020/8/2 | China | 1190 | 1033 | 157 | 535(51.8%) | 100(63.7%) | 55.7±14.1 | 69.3±11.2 |
| Salacup, G. | J Med Virol | 2020/7/4 | USA | 242 | 190 | 52 | 96(50.5%) | 27(51.9%) | 64.1±15.1 | 73.2±11.0 |
| Yu, C.Z. | Am J Prev Med | 2020/6/23 | China | 1464 | 1252 | 212 | 586(46.8%) | 150(70.8%) | 60.5±15.6 | 69.5±10.8 |